EXHIBIT 191



Managed Market Summit October 18, 2012





-02804-DAP Doc #: 1960-85 Filed: 07/23/19 3 of 35. PageID #: 140072 In 2011, Janssen recognized need to better understand the distribution of our products.

- \$600 M of inventory in pipeline at any time
- Optimize initial distribution for several new product launches on horizon
- Maximize return from Levaquin patent expiration
- Improve forecast accuracy
 - IMS vs. NTS
 - Retail inventory
- Leverage new data sources





In 2005, wholesalers began sending us information on their shipments to qualify for a Distributor Performance Agreement (DPA).

■ Key information we receive:

- 852 Wholesalers <u>inventory</u> and <u>total sales</u> out to their customers
- 867 Wholesalers <u>total sales</u> out to their customers <u>broken out by</u>
 Outlet (i.e., Retail Pharmacies, Hospitals, Long Term Care, Clinics, etc. Last Points-of- Care in the Supply Chain where product is shipped prior to delivering to the patients)
- 180 Returns data product that has not been used in the market and is sent back to us for destruction
- 844/849 Chargeback data which identifies how much a vendor qualifies for rebates.

Notes:

- 1. Distributor Performance Agreement is a basis point model, not a true fee-for-service (even though some people in the industry use the terms interchangeably).
- 2. Prompt payment Distributors receive for paying invoices early, this was in place at JOM prior to 2005.





However, wholesalers provide partial 867 information at the zip code level and this limits our ability to generate insights.

- With the help of outside data vendors, we are able to "un-blind and unblock" this information
 - Provides visibility to inventory at retail chain pharmacies
 - Provides visibility of shipments to individual retail stores
- □ This level of visibility was not available prior to 2011.





Case: 1:17-md-02804-DAP Doc #: 1960-85 Filed: 07/23/19 6 of 35. PageID #: 140075

New un-blinded data allowed Janssen to gain a number of new insights.

- □ Shipment volume to pharmacy chains:
 - For example: Nucynta ER sales to Walgreens in 2012 YTD: 31,354 Units and current WAC dollars YTD are \$9.76M
- ☐ Days-on-hand (DOH) inventory at pharmacy chains:
 - For example: CVS DOH for Levaquin was 26 days at the day of patent expration
- ☐ Based on purchasing behavior, we <u>can now identify the most valuable individual pharmacies in the marketplace.</u>
 - For example: 1,027 pharmacies make up the top 3 deciles (8, 9, 10) for Xarelto SPAF
- ☐ We can also identify the top specialty pharmacies for brands like Remicade, Zytiga, Stelara, etc.



Case: 1:17-md-02804-DAP Doc #: 1960-85 Filed: 07/23/19 7 of 35. PageID #: 140076



Un-blinded 867 data also allows us to answer a number of questions from the SCG Trade Group and marketing teams.

- ☐ Insights around purchasing behavior of individual outlets can resolve demand issues and help build demand strategies. For example...
 - Which high decile pharmacies should be targeted for Xarelto DVT launch?
 - Which pharmacies have purchased our product under special offer?
 - •Which outlets are causing erratic demand behavior?
 - •Which outlets are causing high returns?
 - •How long will the inventory with CVS last?
 - •What mix of product strengths are stocked by an outlet?





Analysis of 867 data was critical to the initial distribution for Nucynta and Xarelto.

Case Study presented by:

Paul Lowman, Product Director for Canagliflozin (and former Product Manager for Nucynta ER)



Nucynta ER has a complex product distribution process compared with other drugs





Pharmacist completes the

DEA Form 222 (in triplicate)

to their Wholesaler requesting

the CII Product





Wholesaler validates the Form 222 for completeness and accuracy



CII Order Fulfillment Process - Manual

Validated Form 222 processed at the distribution center and product is picked, packed and shipped to the pharmacy



Patient receives product from the Pharmacy




The pharmacist fills prescription to the patent



The pharmacy obtains reimbursement and Collects the patient co-pay



Automated CSOS (Controlled Substance Order System) **Transaction Flow**





Utilizing 867 data, we were able to create 4 levels of stocking penetration reports for Nucynta ER.

Report Levels	Stakeholders	Key Business Questions Answered		
National View: Weekly Dashboard	Franchise President, Senior Management	 Is initial stocking successful? How many new pharmacies are buying our product weekly? How many pharmacies are placing re-orders weekly? 		
Field Management View: Stocking Penetration	Regional Business Directors and District Managers	■Analyze the penetration against all pharmacies in the region/district		
Sales Reps View: Territory Reports	Sales Reps	Understand stocking status of target pharmacyMonitor and increase penetration		
Consumer View: Pharmacy Locator	Patients/Doctors/Sales Reps	Which pharmacy in my area has Nucynta ER?		




National View - Weekly Dashboard: By week 13, Nucynta ER exceeded its initial stocking goal.

NUCYNTA ER Pharmacy Stocking Launch to date by Strength

	1 Strength	2 Strengths	3 Strengths	4 Strengths	5 Strengths
% Pharm Stocking	60%	21%	10%	5%	3%


NUCYNTA ER Pharmacy Stocking LTD: New vs. Cumulative






Case: 1:17/11/01/02/80/4-12/AP Vice#w1960-85/ Eleck 17/230/9 43/16/55 are get P # 140082 ded insight on product mix and revealed that 100mg strength was capturing 36% of purchases, instead of the expected 20%

NUCYNTA ER Pharmacy Purchase by Strength: Launch to date




NUCYNTA ER Pharmacy Purchase by Strength: Weekly

■ 100mg Bottles



7-md-02804-DAP Doc #: 1960-85 Filed: 07/23/19 14 of 35. PageID #: 140083 Field Management View: RBDs and DMs are able to analyze stocking penetration in their region/district to drive pull through activity.






time, our sales reps know which pharmacies have purchased, and which high decile pharmacies have not purchased our products.

_															
									+				+		
3	Α	В	С	D	- 1	J	K	L	Р	Q	R	S	Υ	Z	AA
	(arelto, Nuc	cynta ER, and N	ucynta - Current 1	13 Weeks <u>Pharmacy Purc</u>	2)			Click the plus sign above to see strength details			:	Click the plus sign above to see strength details			Click the plus sign above to see strength details
							Xarelto	Xarelto			Nucynta EF			Nucynta	Nucynta
							Stocking	Rolling 13	CII		Stocking	Rolling 13		Stocking	Rolling 1
					AC		Status		SAO/LAO			Weeks - # of		Status	Weeks - #
	Barden Non G	Pictulet Name		DOS No.	Market	Xarelto	(Rolling 13	Purchased	Market	ER	(Rolling 13	Purchased	Nucynta	(Rolling 13	
	Region Nam 📢	District Name [,1	Territory Name 🔠	POC Name 🔻		_	_	_	_	_	_	_	_	weeks)	
_			7521402_Phoenix N, AZ		1	2	2	2	1	1	1	2	1	1	4
_		_ 0 ,	7521402_Phoenix N, AZ		1	1	1	1	2	0	0	0	4	2	5
_		_ 0 ,		COSTCO #738 PHARMACY	1	3	2	4	1	3	1	1	1	1	1
_		_ 0 ,	7521402_Phoenix N, AZ		1	1	1	1	1	0	0	0	0	0	0
_	_	_ 0 ,		WALGREENS PHARMACY #9261	0	0	0	0	6	9	5	8	5	2	7
_	_	_ 0 ,		MAYO HOSPITAL ARIZONA OP PHA	0	0	3	7	0	0	0	0	0	0	0
_	_	_ 0 .		APOTHECARY SHOP DEER VALLEY	0	0	2	4	0	0	0	0	0	0	0
_	_		_	WAL-MART PHARMACY 10-#4233	0	0	0	0	2	0	0	0	2	1	1
_	_		_	FRYS FOOD AND DRUG #067	0	0	0	0	1	0	0	0	1	0	0
_	_		_	FRYS FOOD AND DRUG #078	0	0	0	0	2	2	1	1	1	0	0
	_		7521402_Phoenix N, AZ		0	0	0	0	5	0	0	0	1	0	0
	_		7521402_Phoenix N, AZ		1	1	1	1	1	0	0	0	1	1	1
	_		7521402_Phoenix N, AZ		0	0	0	0	1	0	0	0	1	0	0
_	_		7521402_Phoenix N, AZ		1	1	1	1	5	2	1	1	7	1	8
_	_		7521402_Phoenix N, AZ		0	0	0	0	1	0	0	0	0	0	0
_	_		_	WALGREENS PHARMACY #7516	1	0	2	3	1	0	0	0	1	1	1
	_	_ 0		WAL-MART PHARMACY 10-#5329	0	0	0	0	1	0	0	0	1	0	0
	_		-	SCOTTSDALE, PROFESSIONAL PHA	0	0	0	0	0	7	0	0	0	0	0
		_ 0 , , ,	7521402_Phoenix N, AZ		6	8	3	18	6	,	2	4	6	2	8
0	5_Denver, CO	75214_Kingman, AZ	/521402_Phoenix N, AZ	FRYS FOOD AND DRUG #120	0	0	0	0	2	2	1	2	1	0	0
	L / OldDate us	New Oaks / Yes ODC D	Ver CDAT Date /1	histo Date / Catrile Template / Me	discolutions.	/ Ourse Du	alCase / Toke	sial Man Moral	n Non Allin	annual bank	des Tanik	eu DD // 4	11		







Any Other Slides from Paul?





Trade Analytics helps to maximize sales and minimize returns for products at the end of lifecycle.



case: 1:1 Historically, iscends ofton builtuup: excessive inventory at the end of their lifecycles in an effort to maximize sales up to the day of patent expiration.

- ☐ This resulted in large product returns that occurred over the subsequent 24 months as the products reached labeled expiration.
- ☐ Better management of sales and inventories have addressed this problem.





- 1:1 Analysis of distribution data han contributed to better planning for the discontinuation of Prezista 400 mg and Levaquin's patent expiration.
- □For Prezista 400 mg discontinuation: What level of Prezista 400mg inventory will drive fast adoption of Prezista 800mg
 - Minimize lost sales
 - Minimize Prezista 400mg Returns
- ■What level of inventory will minimize Levaquin returns at LOE without jeopardizing sales?
 - Which chains needed help cutting inventories?
 - Where are out-of-stock situations occurring?
 - How large should the return reserve be?





☐ Trade Analytic also helps support in-line Brands:

- Demand Reconciliation
- Retail Inventory Insight
- Improve Incentive Compensation



Demand

Demand Reconciliation

- Deeper insight into distribution data allowed us to validate IMS audits for the first time.
- □ Key business question: Why is there a variance between our NTS sales vs. sales reported by IMS?
 - How can we reduce the Forecast Model error gap related to this?



IMS Demand

Case: 1:17
Wholesale
Demand

Trade Analytics partnered with the Prezista and Invega Sustenna forecasting team to perform demand reconciliations



- □ Prezista brand experienced periodic episodes where total demand (as measured through NPA and DDD) exceeded total ex-factory shipments.
 - These investigations revealed that NPA systematically overstates TRx volume since it does not restate data based on certain reversed/abandoned prescriptions.
 - We learned that projection methodologies between IMS audits differ and this inevitably leads to forecast inaccuracies.
- ☐ Invega Sustenna had opposite situation than Prezista. IMS was reporting lower sales of Invega Sustenna vs. actual ex-factory shipments.
 - Analysis highlighted understatement associated the large panel reporter within the LTC channel
 - Overstatement associated with the reclassification within the Mail Order channel



ase: 1:17-md-02804-DAP Doc #: 1960-85 Filed: 07/23/19 24 of 35. PageID #: 140093



We are developing a standardized approach to estimate retail inventories

- ■Retail inventory has been a historical gap in IMS data.
 - Trade Analytics is currently analyzing Retail Inventory impact to reduce forecast model error.
 - We are also in process of developing standard reports related to Demand Reconciliation that will help forecasters to understand inventory gaps
- □Ultimately, visibility to the entire distribution chain will improve forecasting accuracy and our manufacturing efficiency.



Case: 1: Wholesale Demand

Linking wholesalers build and burn to patient demand provides insights into the estimated retail inventory.

Nucynta ER Wholesale Inventory level by week



Nucynta ER Retail Inventory level by week





New uses of 867 data continue to emerge and we welcome your partnership in developing new applications.

Recent examples..

- □ CNS and Virology Compensation use 867 data to fill gaps in IMS DDD data for new accounts that haven't been captured by IMS
- ☐ CNS is planning to use 867 data to assess a DTC campaign by determining whether sales increased in targeted areas.
- Advanced Analytics group is now incorporating distribution data in their models to increase explanatory power.





Q & A





Back Up



Another key role of Trade Analytics is Manage Loss of Exclusivity

- □We are currently partnering with several teams to ensure minimize returns of Prezista 400mg due to expected Prezista 800mg launch in mid-November
- □ Last year we worked on Levaquin to ensure we get minimum returns due to LOE while making sure that we don't have any stock-outs





PREZISSE A17-md De Borezista BORMENS Priedista A00 mg was ekly Roint Ansore purchase trends at national level by Channel








PREZISSE A17-md-02804-DAP Doc #: 1960-85 Filed: 07/23/19 31 of 35. PageID #: 140100 Prezista 800mg Purchase vs. Prezista 400mg

by Top 25 Points of Care (POCs)

	Prezista 400mg	Prezista 400mg	Prezista 800mg	% of Prezista
	Units	Units	Units (Current	800mg Units
POC Parent - Level 1	(Current 4 Weeks)	(Current Week)	Week)	(Current Week)
UNASSIGNED PARENT (Independent Pharmacies)				
WALGREENS				
CVS				
TEXAS DEPARTMENT OF HEALTH				
BIOSCRIP				
FLORIDA DEPARTMENT OF HEALTH				
RITE AID				
AIDS HEALTHCARE FOUNDATION				
DEPARTMENT OF VETERANS AFFAIRS				
MOMS PHARMACY		onal Level Exa	mole	
OMNICARE		al Exa	IIIIP	
WAL-MART		al Level		
PRESCRIPTION SOLUTIONS	natio	mar		
CARDINAL HEALTH (The Medicine Shoppe)	Mag			
EXPRESS SCRIPTS				
THE APOTHECARY SHOPS OF ARIZONA				
DEPARTMENT OF HEALTH D.C.				
LOS ANGELES GAY AND LESBIAN CENTER				
MCKESSON CORPORATION (Health Mart)				
TARGET				
COMMCARE PHARMACY				
KROGER				
PARKLAND HEALTH & HOSPITAL SYSTEM				
ALABAMA DEPARTMENT OF HEALTH				




Levaquin LOE Strategy Overview 13 we identified Retail Inventory Bubbles...






Purchases and inventory build burn levels throughout the process on weekly basis



- □ Using IntegriChain ECS National tool, we were able to track when retailers stopped warehousing and if the stored began to purchase directly from Wholesalers FDCs
- ☐ IntegriChain MRI tool provided estimation of the retail inventory burn/build on a weekly basis
- □Communicated weekly insight/recommendations to the Trade/JOM Group during weekly process, who transmitted intentions to wholesalers and major retailers to achieve desired results
- Trade Group communicated the inventory reduction strategy to major wholesalers Janssen (ABC, Cardinal, sand, McKesson) and major, retail chains (CVS, Walgreens, Rite Aid, and 32 roger)

Walgreens 7- Sales shift from Hetail warehouse to retail stores and Inventory build/burn



- □ Walgreens had stopped warehousing but due to strong burn, purchases were strong at the retail stores
- ☐ Strong purchases at the Retail stores were alarming as it increased risk of higher returns
- □Communicated weekly insight/recommendations to the Trade/JOM Group during weekly process, who transmitted intentions to wholesalers and major retailers to achieve desired results
 - ■Trade Group communicated the inventory reduction strategy to Cardinal and Walgreens so strong purchase could

of Bottles (Pack Unit)

IMS Demand

Case: 1: Wholesale Demand This is one of the example of the work we had been doing in the Demand

Reconciliation/Retail Inventory area.



